Dateline City:
PHILADELPHIA
...in a Phase 3 Study of Patients with Advanced Melanoma
Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
Merck Plans to Submit sBLA for First-Line Indication in Advanced Melanoma in Mid-2015
PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from the randomized, pivotal Phase 3 study,
KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the
study, KEYTRUDA (pembrolizumab) was statistically superior
to ipilimumab for progression-free survival (PFS), overall survival
(OS), and overall response rate (ORR). On March 24, 2015, Merck
announced that KEYNOTE-006 would be stopped early based on these data (link).
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more